- In February 2025, Tiziana Life Sciences, Ltd. announced the publication of a groundbreaking study in Nature Neuroscience, which revealed that nasal delivery of Tiziana’s anti-CD3 monoclonal antibody notably decreased neuroinflammation and enhanced recovery outcomes
- In July 2024, SanBio Co., Ltd. announced that it had received conditional and time-limited marketing approval in Japan for its human somatic stem cell-processed product, “AKUUGO suspension for intracranial implantation”. The approval covers the use of AKUUGO for improving chronic motor paralysis caused by traumatic brain injury
- In August 2023, Astrocyte Pharmaceuticals Inc. announced the successful completion of an oversubscribed pre-Series B Bridge financing round, raising over USD 6 million. The round was led by Dreavent Capital, with participation from the Alzheimer’s Drug Discovery Foundation and other investors. This funding will support the accelerated clinical development of AST-004, a promising therapeutic candidate targeting a wide range of acute brain injuries, including stroke and traumatic brain injury. In addition, the investment will enable further exploration of AST-004’s potential in preclinical models for Alzheimer’s disease
- In September 2022, Hoth Therapeutics, Inc. announced that it had entered into an agreement with Altasciences, a fully integrated early-phase contract research and manufacturing organization, for the development and production of the HT-TBI drug product formulation. HT-TBI is being developed as an innovative, point-of-care treatment aimed at managing and potentially preventing secondary brain injuries, such as brain swelling and inflammation, associated with ischemic stroke and traumatic brain injury
- In July 2021, Ischemix, Inc. announced that the United States Department of Defense awarded the company 2.9 million dollars to support a Phase 1 clinical study of CMX-2043, an innovative compound designed for the treatment of acute traumatic brain injury. CMX-2043 is a multi-modal, cytoprotective compound derived from a naturally occurring molecule found in the human body. It has previously shown promising safety and effectiveness in preclinical models of traumatic brain injury
